134 related articles for article (PubMed ID: 24634242)
21. Association between X-ray repair cross-complementing group 1(XRCC1) Arg399Gln polymorphism and endometriosis: A systematic review and meta-analysis.
Lv MQ; Wang J; Yu XQ; Hong HH; Ren WJ; Ge P; Zhou DX
Eur J Obstet Gynecol Reprod Biol; 2017 Nov; 218():12-20. PubMed ID: 28926725
[TBL] [Abstract][Full Text] [Related]
22. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.
Yuan Z; Li J; Hu R; Jiao Y; Han Y; Weng Q
Sci Rep; 2015 Nov; 5():16482. PubMed ID: 26585370
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.
Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C
Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935
[TBL] [Abstract][Full Text] [Related]
25. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.
Liu B; Wei J; Zou Z; Qian X; Nakamura T; Zhang W; Ding Y; Feng J; Yu L
Eur J Hum Genet; 2007 Oct; 15(10):1049-53. PubMed ID: 17593927
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
27. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I
Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
[TBL] [Abstract][Full Text] [Related]
29. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
[TBL] [Abstract][Full Text] [Related]
30. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
31. Association of XRCC1 Arg399Gln and Arg194Trp polymorphisms with susceptibility to multiple autoimmune diseases: a meta-analysis.
Peng M; Zhou X; Ding X; Wei L; Zhao Y; Zhu T; Shi X; Qin D
Rheumatol Int; 2017 Mar; 37(3):435-444. PubMed ID: 27812739
[TBL] [Abstract][Full Text] [Related]
32. Quantitative assessment of the association between XRCC1 Arg399Gln and Arg194Trp polymorphisms and risk of cutaneous melanoma.
Jiang H; Xu W; Zhang F; Wei L; Wang Y; Wang Y; Liu C
Melanoma Res; 2016 Jun; 26(3):290-9. PubMed ID: 26967970
[TBL] [Abstract][Full Text] [Related]
33. Associations between XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms and risk of differentiated thyroid carcinoma: a meta-analysis.
Du Y; Han LY; Li DD; Liu H; Gao YH; Sun DJ
Asian Pac J Cancer Prev; 2013; 14(9):5483-7. PubMed ID: 24175846
[TBL] [Abstract][Full Text] [Related]
34. Arg399Gln substitution in XRCC1 as a prognostic and predictive biomarker for prostate cancer: Evidence from 8662 subjects and a structural analysis.
Noureddini M; Mobasseri N; Karimian M; Behjati M; Nikzad H
J Gene Med; 2018 Oct; 20(10-11):e3053. PubMed ID: 30160806
[TBL] [Abstract][Full Text] [Related]
35. Association of DNA repair and xenobiotic pathway gene polymorphisms with genetic susceptibility to gastric cancer patients in West Bengal, India.
Ghosh S; Ghosh S; Bankura B; Saha ML; Maji S; Ghatak S; Pattanayak AK; Sadhukhan S; Guha M; Nachimuthu SK; Panda CK; Maity B; Das M
Tumour Biol; 2016 Jul; 37(7):9139-49. PubMed ID: 26768611
[TBL] [Abstract][Full Text] [Related]
36. The polymorphism of XRCC1 and coronary artery disease risk: a meta-analysis.
Guo SJ; Zhou YT; Liu WY; Zuo QN; Li XH
Eur Rev Med Pharmacol Sci; 2017 Apr; 21(7):1559-1567. PubMed ID: 28429350
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
38. XRCC1 genetic polymorphism Arg399Gln and gastric cancer risk: A meta-analysis.
Geng J; Zhang YW; Huang GC; Chen LB
World J Gastroenterol; 2008 Nov; 14(43):6733-7. PubMed ID: 19034980
[TBL] [Abstract][Full Text] [Related]
39. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
[TBL] [Abstract][Full Text] [Related]
40. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin.
Shim HJ; Yun JY; Hwang JE; Bae WK; Cho SH; Lee JH; Kim HN; Shin MH; Kweon SS; Lee JH; Kim HJ; Chung IJ
Cancer Sci; 2010 May; 101(5):1247-54. PubMed ID: 20331623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
